Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers

• Main Authors: Desmond Y. H. Yap (Author), Jojo Hai (Author), Paul C. H. Lee (Author), Xueying Zhou (Author), Michael Lee (Author), Yu Zhang (Author), Meng Wang (Author), Xiaoxiang Chen (Author)
• Format: Book
• Published: Wiley, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Blockade of the binding between neonatal Fc receptor and IgG‐Fc reduces circulating IgG, and thus emerges as a potential therapy for IgG‐mediated autoimmune conditions. This was a double blind, randomized, single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodyn...